Study title:
AN 2001157844 20010517.
TI Fixed drug eruption due to cyproheptadine hydrochloride (Periactin®).
AU Tanaka-M, Yanaru-E, Hori-K.
IN Dr. M. Tanaka, Division of Dermatology, Kobe National Hospital,
3-1-1, Nishiochiai, Suma-ku, Kobe 654-0155, Japan. SO Skin Research {SKIN-RES}, 2000, Vol/Iss/Pg. 42/6 (567-570), ISSN: 0018-1390. YR 2000.AN 2001157844 20010517.
TI Fixed drug eruption due to cyproheptadine hydrochloride (Periactin®).
AU Tanaka-M, Yanaru-E, Hori-K.
IN Dr. M. Tanaka, Division of Dermatology, Kobe National Hospital,
3-1-1, Nishiochiai, Suma-ku, Kobe 654-0155, Japan. SO Skin Research {SKIN-RES}, 2000, Vol/Iss/Pg. 42/6 (567-570), ISSN: 0018-1390. YR 2000.
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Pathological Conditions, Signs and Symptoms [C23]
|
Brands: Please see report, Please see report |
MAH holders: Please see report |
Assessment: |
Active substance: CYPROHEPTADINE |
ATC code: |
Document link:
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
Y
|
-
|